Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Vaisburd, Sinaya ^a   Shemer, Zeev ^a   Yeheskel, Adva ^a   Giladi, Eliezer ^a   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DAVUNETIDE; DISC1 PROTEIN, MOUSE; DOXYCYCLINE; EB1 PROTEIN, MOUSE; EB3 PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN; NERVE PROTEIN; NEUROPROTECTIVE AGENT; OLIGOPEPTIDE; PROTEIN BINDING; RISPERIDONE;

AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; COGNITION; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HIPPOCAMPUS; HUMAN; MALE; METABOLISM; MOLECULAR DYNAMICS; MOUSE; PATHOLOGY; PHENOTYPE; PROTEIN TERTIARY STRUCTURE; SCHIZOPHRENIA; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; COGNITION; DISEASE MODELS, ANIMAL; DOXYCYCLINE; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR DYNAMICS SIMULATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; PHENOTYPE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RISPERIDONE; SCHIZOPHRENIA;

EID: 84947266958     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16300     Document Type: Article

References (52)

1. St Clair, D. et al. Association within a family of a balanced autosomal translocation with major mental illness. The Lancet 336, 13-16 (1990).
2. Austin, C. P., Ky, B., Ma, L., Morris, J. A. and Shughrue, P. J. Expression of Disrupted-In-Schizophrenia-1, a schizophreniaassociated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience 124, 3-10, doi: 10.1016/j. neuroscience.2003.11.010 (2004).
3. Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V. and Sawa, A. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr Bull 36, 301-313, doi: 10.1093/schbul/sbp133 (2010).
4. Lepagnol-Bestel, A. M., Kvajo, M., Karayiorgou, M., Simonneau, M. and Gogos, J. A. A Disc1 mutation differentially affects neurites and spines in hippocampal and cortical neurons. Mol Cell Neurosci 54, 84-92, doi: 10.1016/j.mcn.2013.01.006 (2013).
5. Harrison, P. J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 174, 151-162, doi: 10.1007/s00213-003-1761-y (2004).
6. Burdick, K. E. et al. DISC1 and neurocognitive function in schizophrenia. Neuroreport 16, 1399-1402, doi: 00001756-200508220- 00028 [pii] (2005).
7. Pletnikov, M. V. et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatr 13, 173-186, doi: 10.1038/sj.mp.4002079 (2008).
8. Oz, S. et al. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry 19, 1115-1124, doi: 10.1038/mp.2014.97 (2014).
9. Gozes, I. N. A. P. (davunetide) provides functional and structural neuroprotection. Current pharmaceutical design 17, 1040-1044 (2011).
10. Divinski, I., Holtser-Cochav, M., Vulih-Schultzman, I., Steingart, R. A. and Gozes, I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 98, 973-984 (2006).
11. Jouroukhin, Y. et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport. Neurobiol Dis 56, 79-94, doi: 10.1016/j.nbd.2013.04.012 (2013).
12. Kumar, P. and Wittmann, T. + TIPs: SxIPping along microtubule ends. Trends in Cell Biology 22, 418-428, doi: 10.1016/j. tcb.2012.05.005 (2012).
13. Nicodemus, K. K. et al. Category fluency, latent semantic analysis and schizophrenia: a candidate gene approach. Cortex; a journal devoted to the study of the nervous system and behavior 55, 182-191, doi: 10.1016/j.cortex.2013.12.004 (2014).
14. Walker, R. M. et al. The DISC1 promoter: characterization and regulation by FOXP2. Hum Mol Genet 21, 2862-2872, doi: 10.1093/hmg/dds111 (2012).
15. Lai, C. S. L., Fisher, S. E., Hurst, J. A., Vargha-Khadem, F. and Monaco, A. P. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature 413, 519-523, (2001).
16. MacDermot, K. D. et al. Identification of FOXP2 Truncation as a Novel Cause of Developmental Speech and Language Deficits. The American Journal of Human Genetics 76, 1074-1080 (2005).
17. Sanjuan, J. et al. FOXP2 polymorphisms in patients with schizophrenia. Schizophr Res 73, 253-256, doi: 10.1016/j. schres.2004.05.012 (2005).
18. Sanjuan, J. et al. Association between FOXP2 polymorphisms and schizophrenia with auditory hallucinations. Psychiatr Genet 16, 67-72, doi: 10.1097/01.ypg.0000185029.35558.bb (2006).
19. Tolosa, A. et al. FOXP2 gene and language impairment in schizophrenia: association and epigenetic studies. BMC Med Genet 11, 114, doi: 10.1186/1471-2350-11-114 (2010).
20. Li, T. et al. FoxP2 is significantly associated with schizophrenia and major depression in the Chinese Han population. World J Biol Psychiatry 14, 146-150, doi: 10.3109/15622975.2011.615860 (2013).
21. Marcus, G. F. and Fisher, S. E. FOXP2 in focus: what can genes tell us about speech and language? Trends in cognitive sciences 7, 257-262 (2003).
22. Gozes, I. et al. Novel Tubulin and Tau Neuroprotective Fragments Sharing Structural Similarities with the Drug Candidate NAP (Davuentide). J Alzheimers Dis, doi: V01L482628837064 (2014).
23. Teague, S. J., Davis, A. M., Leeson, P. D. and Oprea, T. The Design of Leadlike Combinatorial Libraries. Angewandte Chemie 38, 3743-3748 (1999).
24. Congreve, M., Carr, R., Murray, C. and Jhoti, H. A rule of three for fragment-based lead discovery? Drug discovery today 8, 876-877 (2003).
25. Divinski, I., Mittelman, L. and Gozes, I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279, 28531-28538 (2004).
26. Rajagopal, L., Massey, B. W., Huang, M., Oyamada, Y. and Meltzer, H. Y. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des 20, 5104-5114 (2014).
27. Merenlender-Wagner, A., Pikman, R., Giladi, E., Andrieux, A. and Gozes, I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-a microtubule-deficient model of schizophrenia. Peptides 31, 1368-1373, doi: 10.1016/j. peptides.2010.04.011 (2010).
28. Cooke, B. M., Chowanadisai, W. and Breedlove, S. M. Post-weaning social isolation of male rats reduces the volume of the medial amygdala and leads to deficits in adult sexual behavior. Behav Brain Res 117, 107-113 (2000).
29. McIntosh, A. L., Ballard, T. M., Steward, L. J., Moran, P. M. and Fone, K. C. The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology (Berl) 228, 31-42, doi: 10.1007/s00213-013-3011-2 (2013).
30. Zhu, F. et al. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PLoS One 9, e93966, doi: 10.1371/journal.pone.0093966 (2014).
31. Lewis, D. A. and Lieberman, J. A. Catching up on schizophrenia: Natural history and neurobiology. Neuron 28, 325-334, doi: Doi 10.1016/S0896-6273(00)00111-2 (2000).
32. Green, M. F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153, 321-330, doi: 10.1176/ajp.153.3.321 (1996).
33. Javitt, D. C. et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 136, 25-31, doi: S0920-9964(11)00564-0 (2012).
34. Geffen, Y., Keefe, R., Rabinowitz, J., Anand, R. and Davidson, M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. The Journal of clinical psychiatry 73, e1168-1174, doi: 10.4088/JCP.12m07642 (2012).
35. Meltzer, H. Y. and McGurk, S. R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia bulletin 25, 233-255 (1999).
36. Farde, L. et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15, 19S-23S (1995).
37. Alcalay, R. N., Giladi, E., Pick, C. G. and Gozes, I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxietylike behavior in aging mice in the elevated plus maze. Neurosci Lett 361, 128-131 (2004).
38. Sun, T., He, W., Hu, G. and Li, M. Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav 95, 298-307, doi: 10.1016/j.pbb.2010.02.005 (2010).
39. Cabaleiro, T. et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Human psychopharmacology 29, 459-469, doi: 10.1002/hup.2420 (2014).
40. Takahashi, H., Takahashi, K. and Liu, F. C. FOXP genes, neural development, speech and language disorders. Adv Exp Med Biol 665, 117-129 (2009).
41. Shu, W., Yang, H., Zhang, L., Lu, M. M. and Morrisey, E. E. Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. The Journal of biological chemistry 276, 27488-27497, doi: 10.1074/jbc.M100636200 (2001).
42. Fatemi, S. H. et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophrenia research 99, 56-70, doi: 10.1016/j.schres.2007.11.018 (2008).
43. Jarskog, L. F. et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 38, 1245-1252, doi: 10.1038/npp.2013.23 (2013).
44. Honnappa, S. et al. An EB1-binding motif acts as a microtubule tip localization signal. Cell 138, 366-376, doi: 10.1016/j. cell.2009.04.065 (2009).
45. Sun, H. A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption. Journal of chemical information and computer sciences 44, 748-757, doi: 10.1021/ci030304f (2004).
46. Grosdidier, A., Zoete, V. and Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39, W270-277, doi: 10.1093/nar/gkr366 (2011).
47. Schneidman-Duhovny, D. et al. Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins 52, 107-112, doi: 10.1002/prot.10397 (2003).
48. Holtser-Cochav, M., Divinski, I. and Gozes, I. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. Journal of molecular neuroscience: MN 28, 303-307, doi: 10.1385/jmn:28:3:303 (2006).
49. de Bruin, N. and Pouzet, B. Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 85, 253-260, doi: S0091- 3057(06)00264-4 (2006).
50. Pellow, S., Chopin, P., File, S. E. and Briley, M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14, 149-167 (1985).
51. Treit, D., Menard, J. and Royan, C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44, 463-469 (1993).
52. Shiryaev, N. et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 34, 381-388, doi: 10.1016/j.nbd.2009.02.011 (2009).